Limited Coverage Drugs - Glycopyrronium

Generic Name / Strength / Form

glycopyrronium / 50 µg / capsule via inhaler

Special Authority Criteria

Approval Period

Diagnosis of COPD where spirometry measures are:

  • FEV1 as a percentage of predicted value (less than or equal to 65%)

  • Ratio of actual FEV1 / FVC (less than 0.7)

  • Inadequate response after 3 month trial of either:
  • ipratropium at a dose of 12 puffs daily


  • ipratropium and salbutamol combination inhaler (Combivent Respimat) at a dose of 6 puffs daily.1


  1. 12 puffs of ipratropium via inhaler is equivalent to 6 puffs of Combivent Respimat via inhaler.

Practitioner Exemptions

  • Practitioners in the following specialty are not required to submit a Special Authority request form for coverage: Respirology.

Special Notes

  • The dose of glycopyrronium should not exceed 50 mcg per day.
  • In remote areas, where spirometry access is limited, spirometry measurements are to be provided within 6 months.

Special Authority Request Form(s)